Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7186856

COc1cccc(OC)c1C(=O)Pc1ccc(OC(C)(C)C)cc1OC(C)(C)C.[Li]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ KMT2A Q03164 4/20 0.35
▸ AURKA O14965 1/20 0.35
▸ MEN1 O00255 3/20 0.34
▸ GAA P10253 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PPARG P37231 1/20 0.33
▸ PPARD Q03181 1/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ ABCG2 Q9UNQ0 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ ABCB1 P08183 1/20 0.32
▸ PNLIP P16233 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186843 0.97 MAPT (0.40) MAPTCA12CA1CA2CA7
Lithium SCHEMBL7182659 0.94 MAPT (0.38) MAPTCA12CA1CA2CA7
SCHEMBL7182651 0.92 MAPT (0.38) MAPTCA12CA1CA2CA7
Lithium SCHEMBL7183198 0.91 KMT2A (0.44) MAPTKMT2AMEN1SMN1; SMN2ABCG2
SCHEMBL7183190 0.89 KMT2A (0.44) MAPTKMT2AMEN1SMN1; SMN2ABCG2
Lithium SCHEMBL7182112 0.87 POLB (0.35) MAPTKMT2AMEN1PPARGPPARD
SCHEMBL7176063 0.86 CA12 (0.38) MAPTCA12CA1CA2CA7
Lithium SCHEMBL7188999 0.86 KIF11 (0.31) —
SCHEMBL7182105 0.85 POLB (0.35) MAPTKMT2AMEN1PPARGPPARD
Lithium SCHEMBL7177511 0.84 MAPT (0.52) MAPTCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885CA12 1552/4885CA1 2219/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885CA12 1320/4885CA1 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.